ProQR Therapeutics (PRQR)
(Delayed Data from NSDQ)
$2.02 USD
-0.03 (-1.46%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $2.01 -0.01 (-0.50%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for ProQR Therapeutics NV falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -30.02 | -68.37 | -72.97 | -53.25 | -63.56 |
Depreciation/Amortization & Depletion | 2.72 | 2.66 | 2.76 | 2.69 | 2.30 |
Net Change from Assets/Liabilities | 52.99 | -5.73 | 29.57 | -5.86 | 2.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -2.37 | -0.74 | 9.87 | 2.66 | 10.01 |
Net Cash From Operating Activities | 23.32 | -72.18 | -30.77 | -53.76 | -49.25 |
Property & Equipment | -1.42 | -0.74 | -0.50 | -1.06 | -0.65 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 6.05 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 4.63 | -0.74 | -0.50 | -1.06 | -0.65 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.38 | 14.91 | 130.14 | 0.84 | 54.59 |
Issuance (Repayment) of Debt | -1.09 | -45.70 | 32.72 | 16.41 | 3.04 |
Increase (Decrease) Short-Term Debt | -1.75 | -1.76 | -0.97 | -0.69 | -1.41 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -2.46 | -32.55 | 161.89 | 16.56 | 56.22 |
Effect of Exchange Rate Changes | 0.65 | 7.75 | 1.53 | -3.00 | 0.81 |
Net Change In Cash & Equivalents | 26.14 | -97.72 | 132.14 | -41.25 | 7.13 |
Cash at Beginning of Period | 102.58 | 197.58 | 89.72 | 127.88 | 118.25 |
Cash at End of Period | 128.71 | 99.85 | 221.86 | 86.63 | 125.38 |
Diluted Net EPS | -0.38 | -0.96 | -1.14 | -1.06 | -1.55 |
Fiscal Year End for ProQR Therapeutics NV falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -30.02 | -24.22 | -18.35 | -9.50 |
Depreciation/Amortization & Depletion | NA | 2.72 | 1.94 | 1.25 | 0.59 |
Net Change from Assets/Liabilities | NA | 52.99 | 50.78 | 53.07 | 56.13 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | -2.37 | 0.74 | 1.53 | 0.80 |
Net Cash From Operating Activities | NA | 23.32 | 29.25 | 37.49 | 48.01 |
Property & Equipment | NA | -1.42 | -0.79 | -0.42 | -0.10 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 6.05 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 4.63 | -0.79 | -0.42 | -0.10 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.38 | 0.17 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | NA | -1.09 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | -1.75 | -1.46 | -0.99 | -0.28 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | -2.46 | -1.29 | -0.98 | -0.28 |
Effect of Exchange Rate Changes | NA | 0.65 | 0.88 | 0.76 | -0.18 |
Net Change In Cash & Equivalents | NA | 26.14 | 28.06 | 36.84 | 47.46 |
Cash at Beginning of Period | NA | 102.58 | 103.15 | 103.34 | 101.73 |
Cash at End of Period | NA | 128.71 | 131.21 | 140.18 | 149.19 |
Diluted Net EPS | NA | -0.08 | -0.08 | -0.11 | -0.12 |